JP2004217555A - Polyphenol derived from walnut kernel - Google Patents
Polyphenol derived from walnut kernel Download PDFInfo
- Publication number
- JP2004217555A JP2004217555A JP2003005774A JP2003005774A JP2004217555A JP 2004217555 A JP2004217555 A JP 2004217555A JP 2003005774 A JP2003005774 A JP 2003005774A JP 2003005774 A JP2003005774 A JP 2003005774A JP 2004217555 A JP2004217555 A JP 2004217555A
- Authority
- JP
- Japan
- Prior art keywords
- antioxidant
- aromatic
- present
- granulin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000020234 walnut Nutrition 0.000 title abstract description 7
- 235000009496 Juglans regia Nutrition 0.000 title abstract description 5
- 240000007049 Juglans regia Species 0.000 title abstract 2
- 150000008442 polyphenolic compounds Chemical class 0.000 title 1
- 235000013824 polyphenols Nutrition 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 41
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 125000003118 aryl group Chemical group 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 125000002252 acyl group Chemical group 0.000 claims abstract description 16
- 108060003393 Granulin Proteins 0.000 claims description 12
- 102000017941 granulin Human genes 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000007254 oxidation reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 6
- -1 glucoside ascorbate Chemical class 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000758789 Juglans Species 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000012156 elution solvent Substances 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 241000758791 Juglandaceae Species 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 0 C*C(C)C(C(*)C(*)CO*)O*C(C(C1C(C*)C=C(*)C(*)C1C)C1O)=CC(O*)=C1O Chemical compound C*C(C)C(C(*)C(*)CO*)O*C(C(C1C(C*)C=C(*)C(*)C1C)C1O)=CC(O*)=C1O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- WZRRZVUZWWMSKH-UHFFFAOYSA-N n'-naphthalen-1-ylethane-1,2-diamine;hydrochloride Chemical compound Cl.C1=CC=C2C(NCCN)=CC=CC2=C1 WZRRZVUZWWMSKH-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinyl group Chemical group C1(O)=CC(O)=CC=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明は、抗酸化用の組成物に関し、更に詳細には、食品に好適な抗酸化用の組成物に関する。
【0002】
【従来の技術】
酸化は生命活動においては、生命活動の維持に必要なエネルギーを作り出す、重要な化学反応であり、且つ、免疫系において細菌などの侵入非自己生物を攻撃する有用な生体防御手段でもある。しかし、一方、酸化反応、それも生体による制御の効かない酸化反応は生体に大きなダメージを与える。特に、脂質などが酸化されて生じる過酸化物は生体にとって大きな傷害をもたらすし、光老化では過酸化物が大きな要因となっていることが指摘されている。又、炎症においても酸化は大きな役割を果たしており、慢性的な炎症が発ガンの重要因子であることを考えると、酸化は発ガンとも深い関係にあるといえる。即ち、生体において、適切に酸化反応、詳細に言えば、過酸化反応を制御することは、生体の維持と健康の維持にとって大変有用なことであるといえる。この様な目的で、種々の抗酸化剤が使用されており、例えば、この様な抗酸化剤としては、古くはBHT或いはBHAと言った芳香族系の物質が存在し、近年においてはアスコルビン酸、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド等のアスコルビン酸類、トコフェロール類などが存在する。しかしながら、芳香族系の物質については安全性の懸念がぬぐいきれず、アスコルビン酸やその誘導体は、水溶性が高いために生体内での貯留時間に不適切な場合があったり、安定性に問題がある場合があった。(再表平11−59580)トコフェロール類においては、着色や異臭の問題がある場合があり、これらを適度に組み合わせて使用しているのが現状であるといえる。組合せである以上、これらの組合せ素材のみでは対応できない場合があり、すそ野を広げる意味において、新規の抗酸化成分が求められていた。
【0003】
一方、胡桃の抽出物の内、その殻の抽出物中に抗酸化物質が存在することは既に知られているが、(特開2000−72686)仁について、抗酸化物質を含んでいる報告はない。又、後記グランスリンA、B及びCは何れも文献未記載の新規物質であり、従って、この物質が抗酸化作用を有していることも全く知られていない。
【0004】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、新規の抗酸化成分を提供することを課題とする。
【0005】
【課題の解決手段】
この様な状況に鑑みて、本発明者らは、胡桃仁の脱脂物が優れた抗酸化作用を有することを見出し、胡桃仁の脱脂物について、抗酸化作用を指標に分画、スクリーニングを続けた結果、グランスリンA、グランスリンB或いはグランスリンCと言った一般式(1)に表される新規化合物又はその塩がその有効成分であることを見出し、発明を完成させた。即ち、本発明は、以下に示す技術に関するものである。
(1)下記一般式(1)に表される化合物又はその塩。
【0006】
【化5】
一般式(1)
(但し、式中R1、R2、R3、R4、R5、R6、R7、R8、R9はそれぞれ独立に水素原子、炭素数6〜15の芳香族基又は炭素数6〜15の芳香族のアシル基を表し、且つ、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていてもよく、破線の結合はあってもなくても良い。)
【0007】
(2)一般式(1)に表される化合物が、グランスリンA、グランスリンB又はグランスリンCであることを特徴とする、(1)に記載の化合物又はその塩。
【0008】
【化6】
グランスリンA
【0009】
【化7】
グランスリンB
【0010】
【化8】
グランスリンC
【0011】
(3)(1)又は(2)に記載の化合物からなる抗酸化剤。
(4)(3)に記載の抗酸化剤を0.1〜30重量%含有する、活性酸素消去用の経口投与組成物。
(5)食品であることを特徴とする、(4)に記載の経口投与組成物。
【0012】
【発明の実施の形態】
(1)本発明の化合物
本発明の化合物は、一般式(1)に表される構造を有する。かかる化合物は、フェノール性の水酸基を有している為、アルカリなどともに塩の形にして使用することも可能である。かかる塩としては、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩、カルシウム、マグネシウム等のアルカリ土類金属塩、アンモニウム塩、トリエタノールアミン塩、トリエチルアミン塩等の有機アミン塩類、リジン塩、アルギニン塩等の塩基性アミノ酸塩等が好ましく例示できる。一般式(1)に於いて、R1、R2、R3、R4、R5、R6、R7、R8、R9はそれぞれ独立に水素原子、フェニル基、ビフェニル基などの炭素数6〜15の芳香族基又はフェニルカルボニル基、ビフェニルカルボニル基などの炭素数6〜15の芳香族のアシル基を表し、且つ、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていてもよく、破線の結合はあってもなくても良い。ここで、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていても良いとは、例えば、フタロイル基などのように二つ以上のカルボニル基を有する置換基のカルボニル基が糖鎖上の二つ以上の水酸基と反応してジエステルなどを形成するような状況を意味する。即ち、アシル基のカルボニル基以外を共有する場合、アシル基のカルボニル基以外の部分とエーテルを形成する芳香族基が共有されている場合、或いは、レゾルシン残基のように、二つのエーテルの芳香族基が共有されている場合などである。本発明の化合物として、好ましいものは、グランスリンA、グランスリンB及びグランスリンCである。これらの化合物は、胡桃の仁を脱脂した後、極性溶媒で抽出し、液液抽出、カラムクロマトグラフィーなどで精製することにより、製造することが出来る。脱脂はノルマルヘキサンなどの非極性溶剤を使用して抽出することによって行うことが出来る。ジエチルエーテル、イソプロピルエーテル、テトラヒドロフランなどのエーテル類、塩化メチレン、クロロホルムなどのハロゲン化炭化水素類、酢酸エチル、蟻酸メチルなどのエステル類、アセトンやメチルエチルケトン等のケトン類、アセトニトリルなどのニトリル類、1,3−ブタンジオール、エタノール、イソプロピルアルコールなどのアルコール類、水などが好ましく例示できる。これらの内では、アルコール及び/又は水が特に好ましい。抽出は、植物体に対して1〜10重量倍の溶剤を加え、室温であれば数日間、沸点付近の温度であれば数時間浸漬すればよい。抽出後は、必要に応じて、減圧濃縮などして溶剤を除去することが好ましい。又、液液抽出は、ノルマルブタノールと水の溶媒系が好ましく例示できるし、カラムクロマトグラフィーとしては、担体をシリカゲルとして、溶出溶媒をクロロホルム−メタノール系で行うもの、イオン交換樹脂を担体として、水−メタノール系溶媒を溶出溶媒とするものなどが好ましく例示できる。
【0013】
(2)本発明の抗酸化剤
本発明の抗酸化剤は、前記本発明の化合物及び/又はその塩からなることを特徴とする。本発明の化合物は、優れた抗酸化作用を有する為、経口投与組成物に含有させることにより、経口投与組成物中の酸化に弱い成分を酸化から保護することが出来るし、又、消化管より吸収されて体内に分布し、生体成分或いは生体構成成分が酸化するのを防ぐ作用を発揮する。特に、近年の生体酸化関連の研究によれば、生体構成成分の酸化は老化の重要な因子となっており、これを防ぐことにより老化を防止できる蓋然性が高い。従って、本発明の抗酸化剤は、老化防止の目的で使用することが出来る。この様な効果を奏する為には、本発明の抗酸化剤は、組成物中に0.1〜30重量%含有することが好ましく、更に好ましくは、0.2〜10重量%である。又、本発明の抗酸化剤は、本発明の経口投与組成物のみならず、抗酸化剤を用いる他の製剤に含有させることも出来る。かかる製剤としては、皮膚外用医薬や化粧料などの皮膚外用剤が好適に例示できる。この様な製剤に於ける、本発明の抗酸化剤の好適な含有量は、0.01〜10重量%であり、更に好ましくは0.05〜1重量%である。
【0014】
(3)本発明の経口投与組成物
本発明の経口投与組成物は、上記本発明の抗酸化剤を含有することを特徴とする。経口投与組成物としては、経口で投与されるものであれば特段の限定はないが、食品が特に好適に例示できる。食品としては、飴、ガム、焼き菓子などの菓子やソーセージ、ハム、はんぺん、インスタントラーメン等の惣菜などの通常の食品や健康維持や健康促進を目的とする、錠剤や顆粒剤、カプセル剤形式の健康食品或いは特定保険用食品などが好ましく例示できる。通常の食品においては、本発明の抗酸化剤は、酸化から食品を守る目的で使用できる。又、健康維持や健康促進を目的とする、健康食品或いは特定保険用食品などでは、体内に於ける過酸化物の発生や炎症を防ぐ作用を発揮し、老化、発ガンなどを抑制する作用を発揮する。又、アスコルビン酸類やトコフェロール類など酸化を受けやすい有効成分の安定性を高める作用を発揮する。本発明の食品においては、必須成分の抗酸化剤以外に食品で通常使用される任意成分を含有することができる。かかる任意の成分としては、例えば、賦形剤、結合剤、矯味剤、矯臭剤、滑沢剤、被覆剤、増粘剤、乳化剤、分散剤、着色剤、油脂等が好ましく例示できる。これら必須の成分と任意の成分とを常法に従って処理することにより、本発明の食品は製造できる。
【0015】
【実施例】
以下に、実施例を挙げて、本発明について更に詳細に説明を加えるが、本発明が、かかる実施例にのみ限定されないことは言うまでもない。
【0016】
<実施例1>
カシグルミの可食部10kgを圧搾用の型にいれ、35℃条件下、100Kg/cm2で4時間加圧して、油脂分を除去した。圧搾した残りを50%エタノール水溶液で抽出し、濾過して不溶物を除去した後、減圧濃縮して残査310g(本発明の抗酸化用の組成物1)を得た。これを全て、ダイアイオンHP−20(三菱化成製)カラムクロマトグラフィー(溶出溶媒;水:メタノール=100:0〜0:100)およびODSカラムを装着した分取高速液体クロマトグラフィーで精製し、グランスリンAを13mg、グランスリンBを28mg及びグランスリンCを9mg得た。各化合物の物性値は以下の通り。
(グランスリンA)
オフホワイトのアモルファス粉末; [α]D23 −11°(c 0.3, MeOH); ネガティブFABMS m/z 1103 [M−H]−; CD (MeOH) [θ] (nm) +2.3 x 105 (238), −6.9 x 104 (263), +6.0 x 103 (282). 1H NMR (500 MHz, アセトン−d6+重水) δ 7.20 (2H, s), 6.93 (1H, s), 6.62 (1H, s), 6.57 (1H, s), 6.48 (1H, s), 6.38 (1H, s), グルコースプロトンδ6.24 (1H, d, J=8.5 Hz), 5.22 (1H, t, J=9 Hz), 5.48 (1H, dd, J=9, 10 Hz), 5.24 (1H, t, J=10 Hz), 4.54 (1H, dd, J=6.5, 9 Hz), 5.37 (1H, dd, J=6.5, 13 Hz), 3.92 (1H, d, J=13 Hz); 13C NMR(126 MHz, アセトン−d6+重水)δ63.3, 69.1, 73.4, 76.0, 77.0, 92.3, 107.1, 107.3, 107.7, 107.9, 108.3, 110.2 (2C), 114.2 (2C), 115.1, 116.9, 117.5, 119.8, 125.0, 126.0, 126.3, 131.9, 136.1, 136.6, 137.2, 137.4, 139.0,139.4, 139.6, 140.0, 142.4, 144.49, 144.53, 144.9, 145.1, 145.2 (2C), 146.3 (2C), 150.0 (2C), 165.1, 168.11, 168.15, 168.8, 169.4, 172.2.
(グランスリンB)
黄色みがかったアモルファスの粉末; [α]D23 +90°(c 0.1, MeOH); ネガティブFABMS m/: 905 [M−H]−; CD (MeOH) [θ] (nm) +1.9 x 105 (238), −5.6 x104 (266), +1.7 x 104 (285); 1H NMR (500 MHz, アセトン−d6+重水) δ 6.73, 6.71 (1H, in total, each s), 6.60, 6.55 (1H, in total, each s), 6.614, 6.618 (1H, in total, each s), 6.373, 6.368 (1H, in total, each s), 5,947, 5.941 (1H, in total, each s), グルコースプロトンδ5.46 (0.5 H, d,J=4 Hz), 5.08 (0.5 H, dd, J=4, 10 Hz), 5.49 (0.5 H, t, J=10 Hz), 5.12 (0.5 H, t, J=10 Hz), 4.62 (0.5 H, ddd, J=1.5, 6.5, 10 Hz), 5.19 (0.5 H, dd, J=6.5, 13 Hz), 3.83 (0.5 H, dd, J=1.5, 13 Hz)(αアノマー); 5.06 (0.5 H, d, J=8 Hz), 4.87 (0.5 H, dd, J=8, 9 Hz), 5.25 (0.5 H, dd, J=9, 10 Hz), 5.11 (0.5 H, t, J=10 Hz), 4.23 (0.5 H, ddd, J=1, 6.5, 10 Hz), 5.21 (0.5 H, dd, J=6.5, 13 Hz), 3.90 (0.5 H, dd, J=1, 13 Hz)(βアノマー); 13C NMR (126 MHz, アセトン−d6+重水)δ64.1, 64.2, 67.3, 69.7, 70.1, 72.3, 75.6, 75.7, 77.5, 78.3, 91.7, 95.2 (1C), 95.5, 106.77, 106.83, 107.2, 107.30, 107.34, 107.7, 110.4 (1C), 113.9 (1C), 114.3, 114.4, 114.9, 115.0 115.7 (1C), 124.7 (1C), 125.37, 125.42, 126.5 (1C), 126.6, 126.7, 130.2, 130.3, 130.5 (1C), 133.03, 133.05, 135.3 (1C), 135.5 (1C), 136.0, 136.1, 136.2 (1C), 136.4 (1C), 142.1 (1C), 142.2 (1C), 144.3 (1C), 144,4 (1C), 145.0 (1C), 145.13, 145.19, 145.27, 145.32, 145.5 (1C), 145.6 (1C), 167.6, 167.7, 168.1 (1C), 168.9, 169.0, 169.5, 169.6.
(グランスリンC)
黄色みがかったアモルファスの粉末; [α]D23 +79°(c 0.1, MeOH); ネガティブFABMS m/z 933 [M−H]−; CD (MeOH) [θ] (nm) +1.6 x 105 (228), −3.4 x104 (252), +2.8 x 104 (287); 1H NMR (500 MHz, アセトン−d6+重水)δ6.93 (1H, s), 6.89 (1H, s), 6.76 (1H, s), 6.43 (1H, s), グルコースプロトンδ5.65 (1H, d, J=5 Hz), 4.68 (1H, dd, J=2, 5 Hz), 5.49 (1H, t, J=2.5 Hz), 5.12 (1H, dd, J=3, 8 Hz), 4.17 (1H, dd, J=2, 8 Hz), 4.62 (1H, dd, J=3,12 Hz), 3.92 (1H, d, J=12 Hz); 13C NMR (126 MHz, アセトン−d6+重水)δ67.7, 68.3, 68.9, 70.8, 77.0, 77.2, 105.2, 107.5, 109.8, 111.5, 112.7, 114.2, 116.1, 116.5, 116.8, 120.3, 120.5, 124.7, 127.7, 133.4, 135.0, 136.3, 136.6, 138.6, 140.5, 142.4, 143.68, 143.74, 143.9, 144.1, 145.27, 145.33, 145.7, 145.8, 146.3, 148.4, 163.3, 164.9, 168.3, 168.6, 170.3.
【0017】
<実施例2>
キサンチン−キサンチンオキシダーゼ(XOD)系により活性酸素のひとつであるスーパーオキシドアニオン(O2−)を発生させ、発生したO2−の生成率を亜硝酸法により測定し、この値をキサンチンオキシダーゼ阻害活性値で補正して抗酸化作用値を求めた。実施例1で得られた本発明の抗酸化剤を50μg/mlの割合で含有する抗酸化組成物水溶液0.1mlを、65mMリン酸2水素カリウム、35mMホウ酸ナトリウム、0.5mMEDTA2ナトリウム水溶液(以下、緩衝液Aという)0.2ml、0.5mMキサンチン溶液0.2ml、10mMヒドロキシルアミン塩酸塩水溶液0.1ml、純水0.2mlの混合液に、加えてよく撹拌し試験液とした。同様にして、抗酸化用の組成物の代わりに純水0.1mlを用いたコントロールの溶液を作製した上記各試験液及びコントロール溶液に、キサンチンオキシダーゼを1μl/ml濃度で含有する緩衝液Aを0.2ml加えて撹拌した後、37℃で30分インキュベーションした。ブランクとして、上記と同様に調整された試験液及びコントロール溶液に、キサンチンオキシダーゼを含まない緩衝液Aを0.2ml加え、上記と同様に処理した溶液を用意した。このようにして得られた各溶液のそれぞれに、30μMN−1−ナフチルエチレンジアミン塩酸塩、3mMスルファニル酸、25%氷酢酸混液2mlを加え、30分間室温で放置した後、各溶液について、550nmでの吸光度で活性酸素の発生量を、295nmの吸光度で尿酸の発生量を測定した。得られた値を用いて、以下の式に基づき、抗酸化作用値をEC50として算出した。この結果を表1に示す。これより、本発明の化合物であるグランスリンA、B及びCは優れた抗酸化活性を有していることがわかる。尚、この時、アスコルビン酸のEC50値は、34.6 mMであった。
<抗酸化活性を求める式>
活性酸素発生率=[(A550−3−A550−4)/(A550−1−A550−2)]×100
尿酸生成率=[(A295−3−A295−4)/(A295−1−A295−2)]×100
抗酸化活性=100−(活性酸素発生率/尿酸生成率)×100
【0018】
【表1】
【0019】
<実施例3>
下記に示す処方に従って、本発明の食品である錠剤を作成した。即ち、処方成分をフローコーターに仕込み、20重量部の水を噴霧しながら、流動層造粒を行い、3時間40℃で送風乾燥し、顆粒を得た。これを打錠して錠剤を得た。これらの錠剤を無色透明なガラス瓶に詰め、室内で電灯下1週間の露光試験を行った。比較例1として、抗酸化剤を結晶セルロースに置換したものを、比較例2として、抗酸化剤をBHTに置換したものも作成した。対照として、これらのサンプルと同じものを遮光下にも別途保存した。露光試験後、対照と比較して退色の程度を次の基準に従って判定した。即ち、スコア5:対照とほぼ同じ色、スコア4:対照よりやや黄味が薄い、スコア3:対照に比して黄味の薄さが明白に感じられる、スコア2:かなり白い、スコア1:殆ど白であった。結果を表3に示す。これより、本発明の抗酸化用の組成物は酸化による退色を防ぐ作用に優れることがわかる。
結晶セルロース 40重量部
乳糖 20重量部
表2に記載の抗酸化剤 30重量部
リボフラビン 1重量部
ヒドロキシプロピルメチルセルロース 8重量部
ステアリン酸マグネシウム 1重量部
【0020】
【表2】
【0021】
<実施例6>
実施例4の食品を用いて、飲用試験を行った。即ち、3月〜4月の花粉症の季節に花粉症に悩むパネラー1群20名に実施例4の食品(本発明群)又は比較例1の食品(対照群)を1日2回500mgずつ1ヶ月飲用してもらった。その後、その年の花粉症の症状の出方について、(1)いつもの年より良い(2)いつもの年と同じ程度(3)いつもの年より悪いの3者択一の選択で評価してもらった。結果を表3に出現例数として示す。これより、本発明の食品飲用群はいつもの年より花粉症が軽度であったことがわかる。これは、本発明の抗酸化用の組成物により、炎症が抑えられているためと思われる。
【0022】
【表3】
【0023】
【発明の効果】
本発明によれば、新規の抗酸化成分を提供することができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an antioxidant composition, and more particularly to an antioxidant composition suitable for food.
[0002]
[Prior art]
Oxidation is a vital chemical reaction that creates the energy needed to sustain life activity in life activity, and is also a useful biological defense tool that attacks invading non-self organisms such as bacteria in the immune system. However, on the other hand, an oxidation reaction, which is not controlled by the living body, causes great damage to the living body. In particular, it has been pointed out that peroxides generated by oxidation of lipids and the like cause serious damage to living organisms, and that peroxide is a major factor in photoaging. Oxidation also plays a major role in inflammation, and considering that chronic inflammation is an important factor in carcinogenesis, it can be said that oxidation is closely related to carcinogenesis. That is, it can be said that appropriately controlling an oxidation reaction, specifically, a peroxidation reaction, in a living body is very useful for maintaining the living body and maintaining health. For this purpose, various antioxidants have been used. For example, as such antioxidants, aromatic substances such as BHT or BHA existed in the old days, and in recent years, ascorbic acid has been used. , Ascorbic acids such as magnesium phosphate ascorbate and glucoside ascorbate, and tocopherols. However, safety concerns remain with regard to aromatic substances, and ascorbic acid and its derivatives may be inappropriate for storage time in vivo due to their high water solubility, or have problems with stability. There was a case. (Reappearance 11-59580) Tocopherols may have a problem of coloring or offensive odor, and it can be said that at present, these are used in an appropriate combination. As long as it is a combination, there is a case where it is not possible to cope with these combined materials alone, and a new antioxidant component has been demanded from the viewpoint of expanding the field.
[0003]
On the other hand, among the extracts of walnut, it is already known that an antioxidant is present in the extract of the shell, but (Japanese Patent Application Laid-Open No. 2000-72686) has reported that Jin contains an antioxidant. Absent. In addition, all of Gransulin A, B, and C described below are novel substances not described in the literature, and thus it is not known at all that this substance has an antioxidant effect.
[0004]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and it is an object of the present invention to provide a novel antioxidant component.
[0005]
[Means for solving the problem]
In view of such a situation, the present inventors have found that defatted walnuts have an excellent antioxidant effect, and fractionated and screened the defatted walnuts using the antioxidant activity as an index. As a result, the present inventors have found that a novel compound represented by the general formula (1) such as granulin A, granulin B or granulin C or a salt thereof is an active ingredient thereof, and completed the invention. That is, the present invention relates to the following technology.
(1) A compound represented by the following general formula (1) or a salt thereof.
[0006]
Embedded image
General formula (1)
(Wherein, R1, R2, R3, R4, R5, R6, R7, R8, and R9 each independently represent a hydrogen atom, an aromatic group having 6 to 15 carbon atoms, or an aromatic acyl group having 6 to 15 carbon atoms) , And any of the aromatic groups and aromatic acyl groups may have the same substrate as other acyl groups, and may or may not have a bond indicated by a broken line.)
[0007]
(2) The compound according to (1) or a salt thereof, wherein the compound represented by the general formula (1) is granthrin A, granthrin B or granthrin C.
[0008]
Embedded image
Granulin A
[0009]
Embedded image
Granulin B
[0010]
Embedded image
Granulin C
[0011]
(3) An antioxidant comprising the compound according to (1) or (2).
(4) A composition for oral administration for eliminating active oxygen, comprising the antioxidant according to (3) in an amount of 0.1 to 30% by weight.
(5) The composition for oral administration according to (4), which is a food.
[0012]
BEST MODE FOR CARRYING OUT THE INVENTION
(1) Compound of the Present Invention The compound of the present invention has a structure represented by the general formula (1). Since such a compound has a phenolic hydroxyl group, it can be used in the form of a salt together with an alkali or the like. Examples of such salts include alkali metal salts such as sodium salts and potassium salts, alkaline earth metal salts such as calcium and magnesium, ammonium salts, organic amine salts such as triethanolamine salts and triethylamine salts, lysine salts, and arginine salts. And the like can be preferably exemplified. In the general formula (1), R1, R2, R3, R4, R5, R6, R7, R8 and R9 each independently represent a hydrogen atom, an aromatic group having 6 to 15 carbon atoms such as a phenyl group, a biphenyl group or the like. Represents an aromatic acyl group having 6 to 15 carbon atoms such as a phenylcarbonyl group and a biphenylcarbonyl group, and any of the aromatic groups and aromatic acyl groups may have the same base as another acyl group. The connection of the broken lines may or may not be present. Here, any aromatic group or aromatic acyl group may have the same base as another acyl group, for example, a substituent having two or more carbonyl groups such as a phthaloyl group. It means a situation in which a carbonyl group reacts with two or more hydroxyl groups on a sugar chain to form a diester or the like. That is, when a group other than the carbonyl group of the acyl group is shared, when an aromatic group forming an ether is shared with a portion other than the carbonyl group of the acyl group, or when two aromatic groups such as a resorcinol residue are present. For example, when a group is shared. Preferred as the compound of the present invention are Glansulin A, Granulin B and Granulin C. These compounds can be produced by defatting walnut kernels, extracting them with a polar solvent, and purifying them by liquid-liquid extraction, column chromatography or the like. Degreasing can be performed by extraction using a non-polar solvent such as normal hexane. Ethers such as diethyl ether, isopropyl ether and tetrahydrofuran; halogenated hydrocarbons such as methylene chloride and chloroform; esters such as ethyl acetate and methyl formate; ketones such as acetone and methyl ethyl ketone; nitriles such as acetonitrile; Preferred examples include alcohols such as 3-butanediol, ethanol, and isopropyl alcohol, and water. Of these, alcohol and / or water are particularly preferred. Extraction may be performed by adding a solvent in an amount of 1 to 10 times the weight of the plant and immersing it for several days at room temperature or for several hours at a temperature near the boiling point. After the extraction, if necessary, it is preferable to remove the solvent by concentration under reduced pressure or the like. The liquid-liquid extraction can be preferably exemplified by a solvent system of normal butanol and water, and the column chromatography is performed by using silica gel as a carrier, a chloroform-methanol system as an elution solvent, and an ion exchange resin as a carrier. Preferred examples include those using a methanol-based solvent as an elution solvent.
[0013]
(2) Antioxidant of the present invention The antioxidant of the present invention comprises the compound of the present invention and / or a salt thereof. Since the compound of the present invention has an excellent antioxidant effect, by containing it in the composition for oral administration, it is possible to protect the oxidatively weak component in the composition for oral administration from oxidation, It is absorbed and distributed in the body and exerts an effect of preventing oxidation of biological components or biological components. In particular, according to recent studies on biological oxidation, oxidation of biological constituents is an important factor in aging, and it is highly probable that aging can be prevented by preventing this. Therefore, the antioxidant of the present invention can be used for the purpose of preventing aging. In order to exhibit such an effect, the antioxidant of the present invention is preferably contained in the composition in an amount of 0.1 to 30% by weight, more preferably 0.2 to 10% by weight. Further, the antioxidant of the present invention can be contained not only in the composition for oral administration of the present invention but also in other preparations using the antioxidant. As such a preparation, a skin external preparation such as a skin external medicine or a cosmetic can be suitably exemplified. In such a preparation, the preferred content of the antioxidant of the present invention is 0.01 to 10% by weight, more preferably 0.05 to 1% by weight.
[0014]
(3) The composition for oral administration of the present invention The composition for oral administration of the present invention is characterized by containing the above-mentioned antioxidant of the present invention. The composition for oral administration is not particularly limited as long as it can be administered orally, but a food can be particularly preferably exemplified. Foods include candy, gum, baked confectionery and other confectionery and sausages, ham, hampan, instant noodles and other prepared foods, and tablets, granules and capsules for the purpose of maintaining and promoting health. Preferred examples include health foods and foods for specific insurance. In ordinary foods, the antioxidants of the present invention can be used to protect foods from oxidation. In the case of health foods or foods for specified insurance purposes for the purpose of maintaining and promoting health, it has the effect of preventing the generation of peroxides and inflammation in the body and the effect of suppressing aging and carcinogenesis. Demonstrate. Also, it exerts an effect of increasing the stability of active ingredients which are easily oxidized such as ascorbic acids and tocopherols. The food of the present invention may contain optional components usually used in foods in addition to the essential antioxidant. Preferred examples of such optional components include excipients, binders, flavoring agents, flavoring agents, lubricants, coating agents, thickeners, emulsifiers, dispersants, coloring agents, fats, and the like. The food of the present invention can be produced by treating these essential components and optional components in a conventional manner.
[0015]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples, but it is needless to say that the present invention is not limited to only these Examples.
[0016]
<Example 1>
10 kg of the edible portion of the red walnut was put into a pressing mold and pressed at 100 kg / cm 2 for 4 hours at 35 ° C. to remove oils and fats. The compressed residue was extracted with a 50% aqueous ethanol solution, filtered to remove insolubles, and then concentrated under reduced pressure to obtain 310 g of a residue (composition 1 for antioxidation of the present invention). All of this was purified by Diaion HP-20 (manufactured by Mitsubishi Kasei) column chromatography (elution solvent; water: methanol = 100: 0 to 0: 100) and preparative high-performance liquid chromatography equipped with an ODS column. 13 mg of phosphorus A, 28 mg of glansulin B and 9 mg of glansulin C were obtained. The physical properties of each compound are as follows.
(Gran Surin A)
Off-white amorphous powder; [α] D23 −11 ° (c 0.3, MeOH); Negative FABMS m / z 1103 [MH] −; CD (MeOH) [θ] (nm) + 2.3 × 105 (238), -6.9 x 104 (263), +6.0 x 103 (282). 1H NMR (500 MHz, acetone-d6 + heavy water) δ 7.20 (2H, s), 6.93 (1H, s), 6.62 (1H, s), 6.57 (1H, s), 6. 48 (1H, s), 6.38 (1H, s), glucose proton δ 6.24 (1H, d, J = 8.5 Hz), 5.22 (1H, t, J = 9 Hz), 5. 48 (1H, dd, J = 9, 10 Hz), 5.24 (1H, t, J = 10 Hz), 4.54 (1H, dd, J = 6.5, 9 Hz), 5.37 ( 1H, dd, J = 6.5, 13 Hz), 3.92 (1H, d, J = 13 Hz); 13C NMR (126 MHz, acetone-d6 + heavy water) δ 63.3, 69.1, 73.4. , 76.0, 77.0, 92.3, 107.1, 107.3, 107 .7, 107.9, 108.3, 110.2 (2C), 114.2 (2C), 115.1, 116.9, 117.5, 119.8, 125.0, 126.0, 126 1.3, 131.9, 136.1, 136.6, 137.2, 137.4, 139.0, 139.4, 139.6, 140.0, 142.4, 144.49, 144.53. , 144.9, 145.1, 145.2 (2C), 146.3 (2C), 150.0 (2C), 165.1, 168.11, 168.15, 168.8, 169.4, 172.2.
(Gran Surin B)
[Α] D23 + 90 ° (c 0.1, MeOH); Negative FABMS m /: 905 [MH] −; CD (MeOH) [θ] (nm) +1.9 x 105 (238), −5.6 × 104 (266), + 1.7 × 104 (285); 1H NMR (500 MHz, acetone-d6 + heavy water) δ 6.73, 6.71 (1H, in total, each s) ), 6.60, 6.55 (1H, in total, each s), 6.614, 6.618 (1H, total, each s), 6.373, 6.368 (1H, in total, each). s), 5,947, 5.941 (1H, in total, each s), glucose proton δ 5.46 (0.5 H, d, = 4 Hz), 5.08 (0.5 H, dd, J = 4, 10 Hz), 5.49 (0.5 H, t, J = 10 Hz), 5.12 (0.5 H, t, J = 10 Hz), 4.62 (0.5 H, ddd, J = 1.5, 6.5, 10 Hz), 5.19 (0.5 H, dd, J = 6.5, 13 Hz), 3.83 (0.5 H, dd, J = 1.5, 13 Hz) (α anomer); 5.06 (0.5 H, d, J = 8 Hz), 4.87 ( 0.5H, dd, J = 8, 9 Hz), 5.25 (0.5 H, dd, J = 9, 10 Hz), 5.11 (0.5 H, t, J = 10 Hz) , 4.23 (0.5 H, ddd, J = 1, 6.5, 10 Hz), 5.21 (0.5 H, dd, J = 6.5, 13 Hz), 3.90 (0 .5 H, d d, J = 1, 13 Hz) (β anomer); 13 C NMR (126 MHz, acetone-d6 + deuterated water) δ 64.1, 64.2, 67.3, 69.7, 70.1, 72.3, 75 .6, 75.7, 77.5, 78.3, 91.7, 95.2 (1C), 95.5, 106.77, 106.83, 107.2, 107.30, 107.34, 107.7, 110.4 (1C), 113.9 (1C), 114.3, 114.4, 114.9, 115.0 115.7 (1C), 124.7 (1C), 125.37. , 125.42, 126.5 (1C), 126.6, 126.7, 130.2, 130.3, 130.5 (1C), 133.03, 133.05, 135.3 (1C), 135.5 (1C), 136.0, 136.1, 136.2 (1C), 136.4 (1C), 142.1 (1C), 142.2 (1C), 144.3 (1C), 1444 (1C), 145.0 ( 1C), 145.13, 145.19, 145.27, 145.32, 145.5 (1C), 145.6 (1C), 167.6, 167.7, 168.1 (1C), 168. 9, 169.0, 169.5, 169.6.
(Gran Surin C)
[Α] D23 + 79 ° (c 0.1, MeOH); Negative FABMS m / z 933 [MH]-; CD (MeOH) [θ] (nm) +1.6 x 105 (228), -3.4 x 104 (252), +2.8 x 104 (287); 1H NMR (500 MHz, acetone-d6 + heavy water) δ 6.93 (1H, s), 6.89 (1H, s) ), 6.76 (1H, s), 6.43 (1H, s), glucose proton δ 5.65 (1H, d, J = 5 Hz), 4.68 (1H, dd, J = 2, 5 Hz) ), 5.49 (1H, t, J = 2.5 Hz), 5.12 (1H, dd, J = 3, 8 Hz), 4.17 (1H, dd, J = 2, 8 Hz), 4.62 (1H, dd, J = 3,12 Hz), 3.92 (1H, d, J = 12 Hz); 13C NMR (126 MHz, acetone-d6 + heavy water) [delta] 67.7, 68.3, 68.9, 70.8, 77.0, 77. 2, 105.2, 107.5, 109.8, 111.5, 112.7, 114.2, 116.1, 116.5, 116.8, 120.3, 120.5, 124.7, 127.7, 133.4, 135.0, 136.3, 136.6, 138.6, 140.5, 142.4, 143.68, 143.74, 143.9, 144.1, 145. 27, 145.33, 145.7, 145.8, 146.3, 148.4, 163.3, 164.9, 168.3, 168.6, 170.3.
[0017]
<Example 2>
A superoxide anion (O2-), which is one of the active oxygens, is generated by a xanthine-xanthine oxidase (XOD) system, and the generation rate of the generated O2- is measured by a nitrous acid method. After correction, the antioxidant action value was determined. 0.1 ml of an antioxidant composition aqueous solution containing the antioxidant of the present invention obtained in Example 1 at a rate of 50 μg / ml was added to a 65 mM potassium dihydrogen phosphate, 35 mM sodium borate, 0.5 mM EDTA disodium aqueous solution ( The mixture was added to a mixed solution of 0.2 ml of a buffer solution A, 0.2 ml of a 0.5 mM xanthine solution, 0.1 ml of a 10 mM aqueous solution of hydroxylamine hydrochloride, and 0.2 ml of pure water, and stirred well to prepare a test solution. Similarly, a buffer solution containing xanthine oxidase at a concentration of 1 μl / ml was added to each of the above test solutions and control solutions prepared as control solutions using 0.1 ml of pure water instead of the antioxidant composition. After adding 0.2 ml and stirring, the mixture was incubated at 37 ° C. for 30 minutes. As a blank, 0.2 ml of buffer A containing no xanthine oxidase was added to the test solution and control solution prepared in the same manner as above, and a solution treated in the same manner as above was prepared. To each of the thus obtained solutions, 2 ml of a mixture of 30 μM N-1-naphthylethylenediamine hydrochloride, 3 mM sulfanilic acid, and 25% glacial acetic acid was added, and the mixture was allowed to stand at room temperature for 30 minutes. The amount of active oxygen generated was measured by absorbance, and the amount of uric acid was measured by absorbance at 295 nm. Using the obtained value, the antioxidant action value was calculated as EC50 based on the following equation. Table 1 shows the results. This shows that the compounds of the present invention, granthulins A, B and C, have excellent antioxidant activity. At this time, the EC50 value of ascorbic acid was 34.6 mM.
<Equation for determining antioxidant activity>
Active oxygen generation rate = [(A550-3-A550-4) / (A550-1-A550-2)] × 100
Uric acid production rate = [(A295-3-A295-4) / (A295-1-A295-2)] × 100
Antioxidant activity = 100− (active oxygen generation rate / uric acid generation rate) × 100
[0018]
[Table 1]
[0019]
<Example 3>
According to the following prescription, tablets as foods of the present invention were prepared. That is, the prescription components were charged into a flow coater, fluidized-bed granulation was performed while spraying 20 parts by weight of water, and blast-dried at 40 ° C. for 3 hours to obtain granules. This was tableted to obtain a tablet. These tablets were packed in a colorless and transparent glass bottle, and subjected to an exposure test for one week under an electric lamp indoors. As Comparative Example 1, an antioxidant was replaced with crystalline cellulose, and as Comparative Example 2, an antioxidant was replaced with BHT. As a control, the same samples were separately stored under light shielding. After the exposure test, the degree of fading as compared with the control was determined according to the following criteria. That is, score 5: almost the same color as the control, score 4: slightly less yellowish than the control, score 3: light yellowishness is clearly felt compared to the control, score 2: fairly white, score 1: It was almost white. Table 3 shows the results. This indicates that the antioxidant composition of the present invention is excellent in preventing discoloration due to oxidation.
Crystalline cellulose 40 parts by weight Lactose 20 parts by weight Antioxidant described in Table 2 30 parts by weight Riboflavin 1 part by weight Hydroxypropyl methylcellulose 8 parts by weight Magnesium stearate 1 part by weight
[Table 2]
[0021]
<Example 6>
A drinking test was performed using the food of Example 4. That is, the food of Example 4 (the present invention group) or the food of Comparative Example 1 (the control group) was given at a dose of 500 mg twice a day to a group of 20 panelists suffering from hay fever during the season of hay fever from March to April. We had you drink for one month. After that, the way of appearance of the hay fever symptoms of that year was evaluated by three alternatives: (1) Better than usual year (2) Same degree as usual year (3) Worse than usual year received. The results are shown in Table 3 as the number of appearance cases. This indicates that the food and drink group of the present invention had milder hay fever than usual. This is presumably because inflammation was suppressed by the antioxidant composition of the present invention.
[0022]
[Table 3]
[0023]
【The invention's effect】
According to the present invention, a novel antioxidant component can be provided.
Claims (5)
(但し、式中R1、R2、R3、R4、R5、R6、R7、R8、R9はそれぞれ独立に水素原子、炭素数6〜15の芳香族基又は炭素数6〜15の芳香族のアシル基を表し、且つ、何れかの芳香族基、芳香族アシル基は他のアシル基と基体を同じくしていてもよく、破線の結合はあってもなくても良い。)A compound represented by the following general formula (1) or a salt thereof.
(Wherein, R1, R2, R3, R4, R5, R6, R7, R8, and R9 each independently represent a hydrogen atom, an aromatic group having 6 to 15 carbon atoms, or an aromatic acyl group having 6 to 15 carbon atoms) , And any of the aromatic groups and aromatic acyl groups may have the same substrate as other acyl groups, and may or may not have a bond indicated by a broken line.)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003005774A JP4303481B2 (en) | 2003-01-14 | 2003-01-14 | Polyphenols derived from walnut seeds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003005774A JP4303481B2 (en) | 2003-01-14 | 2003-01-14 | Polyphenols derived from walnut seeds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004217555A true JP2004217555A (en) | 2004-08-05 |
| JP2004217555A5 JP2004217555A5 (en) | 2005-09-22 |
| JP4303481B2 JP4303481B2 (en) | 2009-07-29 |
Family
ID=32896347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003005774A Expired - Fee Related JP4303481B2 (en) | 2003-01-14 | 2003-01-14 | Polyphenols derived from walnut seeds |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4303481B2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006052184A (en) * | 2004-08-16 | 2006-02-23 | Pola Chem Ind Inc | Food for inhibiting oxidation stress |
| JP2009538871A (en) * | 2006-06-02 | 2009-11-12 | アルティントン ビジネス,エセ.エレ. | Walnut isolated extract, its acquisition and use |
| MD4299C1 (en) * | 2013-09-16 | 2015-03-31 | Институт Генетики И Физиологии Растений Академии Наук Молдовы | Process for producing antioxidant compounds from walnut kernel skin (Juglans regia L.) |
| MD855Z (en) * | 2014-01-29 | 2015-07-31 | Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы | Process for preparing antioxidant compounds from kernel peel of walnut Juglans regia L. |
| CN106805180A (en) * | 2017-01-13 | 2017-06-09 | 江南大学 | A kind of method that polyphenol substance is extracted in desmoenzyme and the ultrasonically treated endotesta walnut kernel by band |
| WO2021002823A1 (en) * | 2019-07-04 | 2021-01-07 | Petro-Yağ Ve Ki̇myasallar Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Coolant for electronic equipment used in cryptocurrency mining |
-
2003
- 2003-01-14 JP JP2003005774A patent/JP4303481B2/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006052184A (en) * | 2004-08-16 | 2006-02-23 | Pola Chem Ind Inc | Food for inhibiting oxidation stress |
| JP2009538871A (en) * | 2006-06-02 | 2009-11-12 | アルティントン ビジネス,エセ.エレ. | Walnut isolated extract, its acquisition and use |
| MD4299C1 (en) * | 2013-09-16 | 2015-03-31 | Институт Генетики И Физиологии Растений Академии Наук Молдовы | Process for producing antioxidant compounds from walnut kernel skin (Juglans regia L.) |
| MD855Z (en) * | 2014-01-29 | 2015-07-31 | Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы | Process for preparing antioxidant compounds from kernel peel of walnut Juglans regia L. |
| CN106805180A (en) * | 2017-01-13 | 2017-06-09 | 江南大学 | A kind of method that polyphenol substance is extracted in desmoenzyme and the ultrasonically treated endotesta walnut kernel by band |
| CN106805180B (en) * | 2017-01-13 | 2020-08-07 | 江南大学 | Method for extracting polyphenol substance from walnut kernel with inner seed coat by combining enzyme and ultrasonic treatment |
| WO2021002823A1 (en) * | 2019-07-04 | 2021-01-07 | Petro-Yağ Ve Ki̇myasallar Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Coolant for electronic equipment used in cryptocurrency mining |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4303481B2 (en) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7829591B2 (en) | Flavanone compound and uses thereof | |
| JP4376977B2 (en) | Lipase inhibitors, food additives and food | |
| JP4205943B2 (en) | Bioavailable compositions of natural and synthetic HCA | |
| WO1999055298A1 (en) | Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis | |
| CN1394139A (en) | Anticancer agents | |
| JP2004217555A (en) | Polyphenol derived from walnut kernel | |
| TWI284529B (en) | A composition for lowering triglyceride | |
| JP2005501867A (en) | Novel ascorbic acid compound, its synthesis method and its use | |
| JP7578315B1 (en) | Nrf2 activator | |
| JP4325908B2 (en) | Lipolysis accelerator, skin external preparation and food and drink using the same | |
| JP7506903B2 (en) | IL-37 production promoter | |
| JP2006052184A (en) | Food for inhibiting oxidation stress | |
| JP4034984B2 (en) | Antioxidant composition | |
| JP2000273452A (en) | Antioxidant | |
| JP2004107314A (en) | Oral administration formulation for antioxidation | |
| JP3976890B2 (en) | Novel compounds or pharmacologically acceptable salts thereof and antioxidants containing them as active ingredients | |
| JP2004269415A (en) | Antioxidant | |
| CN112972441B (en) | Application of monocarbonyl curcumin compound in preparation of medicine for preventing and treating periodontitis | |
| CA2345409C (en) | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis | |
| JP5236593B2 (en) | Lipolysis accelerator | |
| JP4509524B2 (en) | High density lipoprotein cholesterol level increasing agent in blood | |
| JP2000247880A (en) | Fat decomposition-accelerating agent | |
| JP2001097992A (en) | New polyol-based compound | |
| KR101481040B1 (en) | Composition for anti-inflammation comprising [10]-gingerdione or 1-dehydro-[10]-gingerdione | |
| KR20060121273A (en) | remedy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050414 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050414 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090213 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090421 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090424 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150501 Year of fee payment: 6 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |